Click image to enlarge
Please note: MSD has transitioned this product to a status of “made-to-order” with a minimum order size of 25 plates. For an order of the 5-plate pack size, the minimum quantity is 5 packs (25 plates). The 1-plate and 25-plate pack sizes have been discontinued.
-
-
Specifications
-
Kit Contents
-
Documentation
-
References
|
Product Description
|
Storage
|
Quantity per Kit
|
|
Phosphatase Inhibitor I 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Phosphatase Inhibitor II 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
Protease Inhibitor Solution 0.5mL
|
2-8 °C
|
1 each
(1 each)
|
|
|
|
SULFO-TAG Anti-Total EGFR (Cyto) Antibody
|
2-8 °C
|
1 vial
|
|
|
|
Total EGFR (Cyto) Plate
|
2-8 °C
|
5 each
(1 each)
|
|
|
|
|
2-8 °C
|
1 bottle
(50 mL)
|
|
|
|
|
2-8 °C
|
1 bottle
(200 mL)
|
|
|
|
|
RT
|
1 bottle
(50 mL)
|
|
|
|
|
RT
|
1 bottle
(15 g)
|
|
|
|
|
≤-10 °C
|
1 vial
(1.8 mL)
|
|
|
|
|
≤-10 °C
|
1 vial
(1 mL)
|
|
|
|
Title
|
Journal
|
Year
|
|
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
|
|
|
|
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
|
|
|
|
Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody.
|
|
|
|
Multiplexing siRNAs to compress RNAi-based screen size in human cells.
|
|
|
|
|
|
Order Details
Catalog No
Size
Price in USD
Qty
Meso Scale Japan 株式会社